Since a number of specific receptors (GPR40, GPR41, GPR43, GPR119, and GPR120) expressed on the enteroendocrine L- and K-cells were discovered, there has been an increasing interest in making new effective drugs to treat type 2 diabetes mellitus and metabolic syndrome (4). This evidence concerns the gene GPR119 and type 2 diabetes mellitus.